Evaluation of the Safety and Efficacy of Rimonabant on Cognitive impairment in patients with post-COVID-19 Syndrome.
Key facts
- Where
- Albacete, Madrid, San Sebastián és Toledo, SpanyolországSee the 4 sites
- Phase
- 2. fázis
Where in Spanyolország
- Hospital General Universitario de AlbaceteAlbacete, SpanyolországTaking people
- Hospital Clínico San CarlosMadrid, SpanyolországTaking people
- ATHENEA NeuroclinicsSan Sebastián, SpanyolországTaking people
- Hospital Nacional De ParaplejicosToledo, SpanyolországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sinfatin S.L.
- Trial code
- EU 2023-507870-42-00
- Record updated
- 2026. szeptember 28.
- Original description
To evaluate the efficacy of rimonabant in improving cognitive impairment in patients with post-COVID-19 syndrome compared to placebo.Read full original descriptionShow less
Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on the Improvement of Cognitive Impairment in Patients with Post-COVID-19 Syndrome (RIMOCOVID-1)
To evaluate the efficacy of rimonabant in improving cognitive impairment in patients with post-COVID-19 syndrome compared to placebo.
Inclusion: Be aged between 18 and 75 years (both inclusive); Have had COVID-19 at least 3 months before joining the study; Have been diagnosed with active PCS (Long COVID); Have ongoing problems with memory or concentration due to long-COVID syndrome; Show signs of cognitive impairment in study assessments; Be willing to complete study assessments; Be able to understand and speak Spanish; Provide written consent to participate; Indication of brain fog symptoms: BFS (Brain Fog Scale) ≥ 47.
Exclusion: Use substances or medications that may affect memory or concentration; Have severe mental health conditions (as per clinical records): major depressive disorder; severe anxiety disorder; bipolar disorder; schizophrenia or schizoaffective disorder; psychotic disorder; previous suicide attempt; any psychiatric disorder requiring psychiatric hospitalization; any other severe psychiatric condition that, in the investigator's opinion, may compromise participant safety or interfere with study; Have an active or recent COVID-19 infection; Have other medical conditions that could explain their symptoms; Have severe lung, heart, liver, kidney, or bone disease; Major depressive disorder or severe anxiety disorder, according to DSM-5-TR criteria: Scores ≥ 20 on the BDI-II or ≥ 11 on the HADS at screening, followed by the confirmation of the diagnosis by a health professional (psychologist or psychiatrist); Have a known allergy to rimonabant; Have neurological conditions that may affect memory or concentration; Have a body mass index (BMI) greater than 40 kg/m²; Are unable to walk or attend study visits; Are taking medicines that may interact with the study treatment; Have taken part in another clinical trial within the last month; Are pregnant or breastfeeding; Are able to become pregnant or father a child and are not using effective contraception; Have a high risk of suicide.